Polygon Science-1

CAR-γδ T Cell Technology
(CTM-N2D Therapy)

Unlike the conventional CAR-T cell technology that relies on the use of patient blood cells to generate highly personalized αβ T cell-based therapy for certain cancer, our CAR-γδ T cell technology enable the use of donor blood cells as starting materials to manufacture “off-the-shelf” therapy (CTM-N2D therapy) to target stress-induced cancer antigens for a wide spectrum of cancers for many patients.

Manufacturing Process of CAR-γδ T Cells (CTM-N2D Therapy)


Key Product features of CAR-γδ T cells
(CTN-N2D Therapy)

  • Built-in receptors
  • NKG2DL-targeting CAR
  • Safer product
  • "Off-the-shelf"
  • For various cancers
  • For many patients

CytoMed’s CAR-γδ T Cells vs Conventional CAR-T Cells:
Technology, Manufacture and Implications

Source of starting material Patient blood cells, potential issues include:
  • Limited cell number due to leukopenia or young age;
  • Poor cell quality due to patient's conditions or previous treatments;
  • Contamination of leukaemia cells or circulating tumour cells
Healthy donor blood cells, advantages include:
  • Guaranteed cell number;
  • Reasonable cell quality;
  • No contamination of cancer cell
Collection of starting material Invasive leukapheresis to collect immune cells Simple blood draw to collect blood sample
Manufacturing process A complicated manufacturing process includes:
  • Washing leukocytes out of apheresis products using a cell washer;
  • Enriching lymphocytes via counterflow centrifugal elutriation;
  • Expanding and transducing T cells using beads and lentiviral vectors
A simple manufacturing process includes:
  • Mononuclear cell isolation;
  • γδ T cell expansion;
  • mRNA electroporation
Method to install CAR Lentivirus, potential issues include:
  • Risk of secondary cancers due to insertional mutagenesis or contamination of cancer cells in the finished products;
  • Risk of long-term adverse effects due to persistence of CAR-αβ T cells;
mRNA electroporation, advantages include:
  • No risk of secondary cancers;
  • No risk of long-term adverse effects;
Target antigen Lineage-specific antigen(e.g. CD19), which expresses in both malignant cells and normal cells and cause “on-target off-cancer” side effect. Stress-induced antigens (e.g. NKG2DLs and phosphoantigen), which mainly express on cancer cells and reduce the risk of “on-target off-cancer” side effect.
Finished product CAR-grafted αβ T cells CAR-grafted γδ T cells
Application setting Autologous use, applicable to a single patient only Allogeneic use, applicable to many patients
Indication For haematological malignancies so far For solid tumors and haematological malignancies
Industrial implication Highly personalized “made-to-order” product, expensive “Off-the-shelf” product, affordable